Professor Hou Hsin-An: Deepening Cross-Strait Hematology Exchange and Exploring New Pathways for Precision Diagnosis and Treatment | 2026 Cross-Strait Hematology Conference

Professor Hou Hsin-An: Deepening Cross-Strait Hematology Exchange and Exploring New Pathways for Precision Diagnosis and Treatment | 2026 Cross-Strait Hematology Conference

In the golden autumn season, the Greater Bay Area comes alive, as colleagues from across the mountains and seas come together. The 2026 Cross-Strait Hematology Conference was held with great success in Zhuhai, Guangdong, from August 21–22. Hematology experts and scholars from mainland China, Taiwan, Hong Kong, and Macao gathered to engage in in-depth discussions on topics including cutting-edge developments in the field, clinical practice, and nursing innovation. During the conference, Professor Hou Hsin-An, Conference Chair and President of the Taiwan Society of Hematology, spoke with the media. Drawing on the strong foundation and broad prospects for hematology exchange across the Taiwan Strait, Professor Hou shared forward-looking perspectives on key topics including deepening academic exchange and collaborative cooperation, advancing precision diagnosis and treatment of hematologic diseases, and promoting the development and growth of young hematology professionals.
Professor Lanping Xu: Joining Forces in the Greater Bay Area to Build a New Platform for Hematology Exchange Across the Mainland, Taiwan, Hong Kong, and Macao | 2026 Cross-Strait Hematology Conference%

Professor Lanping Xu: Joining Forces in the Greater Bay Area to Build a New Platform for Hematology Exchange Across the Mainland, Taiwan, Hong Kong, and Macao | 2026 Cross-Strait Hematology Conference%

In the golden autumn season, colleagues from across the mountains and seas came together. The 2026 Cross-Strait Hematology Conference was held in Zhuhai, Guangdong, on August 21–22, bringing together hematology experts and scholars from the Chinese mainland, Taiwan, Hong Kong, and Macao to engage in in-depth discussions on advances in the field, clinical practice, and nursing innovation. During the conference, Professor Lanping Xu of Peking University People's Hospital, Chair of the Hematology Committee of the Cross-Strait Medical and Health Exchange Association and Conference Chair, spoke with the media about the conference agenda, complementary strengths in hematopoietic stem cell transplantation across the mainland and Taiwan, and the long-term value of the academic platform.
The 14th Lu Daopei Hematology Forum丨Professor Huili Zhu: Evidence-Based Updates and Precision Prevention and Control — A Clinical Interpretation of the 7th Edition of the Guidelines for Invasive Fungal Disease in Hematologic Disorders

The 14th Lu Daopei Hematology Forum丨Professor Huili Zhu: Evidence-Based Updates and Precision Prevention and Control — A Clinical Interpretation of the 7th Edition of the Guidelines for Invasive Fungal Disease in Hematologic Disorders

Bringing together leading experts in the field, the 14th Lu Daopei Hematology Forum opened on August 21, 2026, at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic development, this year’s conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic disorders. The conference brought together leading experts and scholars from across China to discuss the future development of hematology and served as an important platform for advancing the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Professor Huili Zhu from Lu Daopei Hospital to share her insights into the updated 7th edition of the guidelines for invasive fungal disease (IFD) in patients with hematologic disorders, focusing on the background of the update, key changes, and strategies for clinical implementation.
AIDS 2026 | Dr. Vizcaino: Focus on Harms of Late HIV Diagnosis in Cuba and Explore Efficient Early Diagnosis, Prevention and Control Strategies

AIDS 2026 | Dr. Vizcaino: Focus on Harms of Late HIV Diagnosis in Cuba and Explore Efficient Early Diagnosis, Prevention and Control Strategies

The 2026 International AIDS Conference was held in Rio de Janeiro, Brazil, where scholars from across the globe engaged in in-depth exchanges on the latest advances in HIV diagnosis, treatment, prevention and control. Dr. Milena Duque Vizcaino from the Pedro Kourí Tropical Medicine Institute in Cuba presented a domestic follow-up study covering 2019 to 2025 at the conference, centering on the critical public health issue linking late HIV diagnosis to mortality risk. Though Cuba has built a comprehensive HIV prevention and control network underpinned by its unique universal free healthcare system, the challenge of delayed diagnosis has not been fully eliminated. Infectious Disease Frontier conducted an exclusive interview with Dr. Vizcaino to discuss core topics including disparities in mortality risk among late-diagnosed patients, key barriers to delayed diagnosis, and optimized screening and intervention pathways. The interview analyzes pain points and practical experience of HIV prevention under a Latin American medical model, offering reference frameworks for low- and middle-income regions worldwide to refine strategies for early HIV screening and treatment.
Professor Shaogang Wang: Technological Innovation Enabling Precision Minimally Invasive Surgery, with Clinical Research Driving the Future of Urology

Professor Shaogang Wang: Technological Innovation Enabling Precision Minimally Invasive Surgery, with Clinical Research Driving the Future of Urology

In recent years, urology has entered an important period of rapid technological iteration and continuous evolution in treatment concepts. From the accelerated development of advanced domestically manufactured medical equipment to the growing integration of robotic-assisted surgery, molecular imaging, and artificial intelligence into clinical practice, urology is moving toward increasingly minimally invasive, precise, and function-preserving approaches. At the same time, high-quality clinical research has become an important foundation for updating treatment standards and strengthening China's academic influence in urology. Oncology Frontier – UroStream invited Professor Shaogang Wang of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, for an in-depth interview. He shared his perspectives on trends in urological development, the clinical value and technological advances of robotic-assisted surgery, and strategies for conducting high-quality clinical research.
Prof. Liang Huang: From “One-Size-Fits-All” to “Tailored Treatment” — De-escalation and Advancement in Individualized Surgical Management of Breast Cancer | 2026 Lingnan Breast Cancer Academic Forum

Prof. Liang Huang: From “One-Size-Fits-All” to “Tailored Treatment” — De-escalation and Advancement in Individualized Surgical Management of Breast Cancer | 2026 Lingnan Breast Cancer Academic Forum

Breast cancer surgery is undergoing a profound transformation, shifting from “maximum tolerable surgery” toward “minimum effective treatment.” How to precisely “do less” while maintaining oncologic efficacy, and how to redefine the role of surgery throughout the disease course, have become major topics of clinical discussion. Recently, at the 2026 Lingnan Breast Cancer Academic Forum, Oncology Frontier interviewed Prof. Liang Huang of Fudan University Shanghai Cancer Center. Drawing on his extensive clinical experience, Prof. Huang shared his insights into individualized surgical decision-making, the evidence supporting axillary de-escalation strategies, and the transformation of surgeons into “whole-course disease managers,” offering practical perspectives on balancing established principles with innovation in breast cancer surgery in the era of precision medicine.
First Global Guideline for the Integrated Evaluation of Evidence on the Efficacy of Traditional Chinese Medicine Published

First Global Guideline for the Integrated Evaluation of Evidence on the Efficacy of Traditional Chinese Medicine Published

Recently, the China Association of Chinese Medicine (CACM) Group Standard, Integrated Evaluation of Evidence on the Efficacy of Traditional Chinese Medicine was officially released in Beijing. As the world’s first guiding standard for the integrated evaluation of evidence on the efficacy of traditional Chinese medicine (TCM), the standard was jointly developed under the leadership of Researcher Xiao Xiaohe, Professor Wang Jiabo, Academician Tian Jinzhou, Academician Chen Xiangmei, and Professor Dai Aiguo, with the participation of more than 60 leading experts from 13 universities, research institutes, medical institutions, and pharmaceutical companies across China, including the Chinese PLA General Hospital, Capital Medical University, Beijing University of Chinese Medicine, and Hunan University of Chinese Medicine.
Pujiang Prostate Cancer Academic Conference | Prof. Fangning Wan: Innovations in Local Therapy, Advances in Systemic Treatment, and Clinical Applications of Cryotherapy for Prostate Cancer

Pujiang Prostate Cancer Academic Conference | Prof. Fangning Wan: Innovations in Local Therapy, Advances in Systemic Treatment, and Clinical Applications of Cryotherapy for Prostate Cancer

The 2026 Pujiang Prostate Cancer Academic Conference was held in Shanghai from June 26–27, 2026. As treatment strategies for prostate cancer continue to evolve, local therapy has progressed beyond conventional radical surgery toward robot-assisted precision surgery with greater emphasis on functional preservation. Meanwhile, focal therapies such as cryoablation and irreversible electroporation (IRE) have emerged as promising treatment options for carefully selected patients.
Advances in ADC Therapy for Advanced Urothelial Carcinoma | Prof. Kaiwei Yang Reviews the Evolving First- and Later-Line Treatment Landscape

Advances in ADC Therapy for Advanced Urothelial Carcinoma | Prof. Kaiwei Yang Reviews the Evolving First- and Later-Line Treatment Landscape

The treatment landscape for advanced urothelial carcinoma (UC) has entered a new era. Antibody-drug conjugates (ADCs) targeting Nectin-4, HER2, and Trop-2 have rapidly transformed clinical practice, while ADCs combined with immune checkpoint inhibitors have become the new standard for first-line treatment. At the 2026 CSCO Annual Meeting, Prof. Kaiwei Yang from the Department of Urology, Peking University First Hospital presented a comprehensive overview of the current evidence supporting approved and investigational ADCs. Drawing on the latest 2026 CSCO Guidelines, he systematically reviewed first-line treatment strategies, sequencing after disease progression, breakthroughs in domestically developed ADCs, and the next generation of emerging targets, providing valuable insights into individualized treatment for advanced urothelial carcinoma.
CUDA 2026 | Rethinking Tiered Healthcare and Multidisciplinary Care in Urology—An Interview with Prof. Zhisong He

CUDA 2026 | Rethinking Tiered Healthcare and Multidisciplinary Care in Urology—An Interview with Prof. Zhisong He

The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou under the theme "Collaboration and Innovation." The conference focused on key topics including precision diagnosis and treatment of urologic diseases, comprehensive cancer management, and multidisciplinary team (MDT) care, showcasing China's latest advances in technological innovation and the standardization of clinical practice.